						et 1 of 5
U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			ATTY. DOCKET NO. MNM/002		APPLN. NO. 10/659,000	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			APPLICANTS Michael W. Pantoliano et al.		CONFIRMATION NO 4943	
NOV. 1 2 2004			FILING DATE September 9, 2003		GROUP 1645	
	US	PATENT DOC	UMENTS			
DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLAS	s	NG DATE IF ROPRIATE
	FORE	GN PATENT D	OCUMENTS			
DOCUMENT NUMBER	DATE	COUNTR	Y CLASS	SUBCLAS	s	NSLATION NO
					120	
OTHER DOC	UMENTS (Inc	cluding Author, 1	itle, Date, Pertinen	t Pages, Etc.))	
				Hypertherm	ophilic Arcl	naeon
	DOCUMENT NUMBER OTHER DOCUMENT NUMBER	PATENT AND TRADEMA INFORMATION DISCLOSURE STATEMENT BY APPLICANT U.S DOCUMENT NUMBER DATE FORE DOCUMENT NUMBER OTHER DOCUMENTS (Inc. Arndt et al., "Crystal Structure of	PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT U.S. PATENT DOC DOCUMENT NUMBER POREIGN PATENT DO DOCUMENT NUMBER DATE COUNTR OTHER DOCUMENTS (Including Author, T	PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT U.S. PATENT DOCUMENTS DOCUMENT NUMBER PATENT DATE FOREIGN PATENT DOCUMENTS DOCUMENT NUMBER DATE CLASS OTHER DOCUMENTS (Including Author, Title, Date, Pertinen	PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT U.S. PATENT DOCUMENTS DOCUMENT NUMBER POREIGN PATENT DOCUMENTS FOREIGN PATENT DOCUMENTS DOCUMENT NUMBER CLASS SUBCLAS FOREIGN PATENT DOCUMENTS OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Arndt et al., "Crystal Structure of a Novel Carboxypeptidase from the Hypertherm	PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT U.S. PATENT DOCUMENTS DOCUMENT NUMBER POREIGN PATENT DOCUMENTS FOREIGN PATENT DOCUMENTS DOCUMENT NUMBER DATE CLASS SUBCLASS FILI APPR FOREIGN PATENT DOCUMENTS TRAI YES OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Brown et al., "Structure of Neurolysin Reveals a Deep Channel that Limits Substrate Access," Proc. Natl. Acad. Sci. USA 98:3127-3132 (2001).

Christianson and Lipscomb, "Carboxypeptidase A," Acc. Chem. Res. 22:62-69 (1989).

Cohen et al., "Molecular Modeling Software and Methods for Medicinal Chemistry," J. Med. Chem. 33:883-894 (1990).

Crackower et al., "Angiotensin-Converting enzyme 2 is an Essential Regulator of Heart Function," Nature 417:822-828 (2002).

Dales et al., "Substrate-Based Design of the First Class of Angiotensin-Converting Enzyme-Related Carboxypeptidase (ACE2) Inhibitors," J. Am. Chem. Soc. 124:11852-11853 (2002).

Danilczyk et al., "A Story of Two ACEs," J. Mol. Med. 81:227-234 (2003).

EXAMINER

N Street

DATE CONSIDERED

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

ATTY. DOCKET NO.	APPLN. NO.
MNM/002	10/659,000
APPLICANTS Michael W. Pantoliano et al.	CONFIRMATION NO. 4943
FILING DATE	GROUP
September 9, 2003	1645

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
we	Donoghue et al., "A Novel Angiotensin-Converting Enzyme-Related Carboxypeptidase (ACE2) Converts Angiotensin I to Angiotensin 1-9," Circ. Res. 87:e1-e9 (2000).						
Nl	Ehlers et al., "Molec Isozyme is Identica Acad. Sci. USA 86:	I to the C-Ter	of Human Testicular Ar minal Half of Endothelia 989).	ngiotensin-C al Angiotensi	onverting Enzym in-Converting En	ne: the Testis ezyme," <i>Proc. Natl.</i>	
me	Esther et al., "Mice Pathology, and Red	Lacking Angi duced Male F	otensin-Converting Enzertility," Lab Invest. 74:	yme Have L 953-965 (199	ow Blood Pressi 96).	ure, Renal	
Ne	Fernandez et al., "Angiotensin I-Converting Enzyme Transition State Stabilization by His ¹⁰⁸⁹ : Evidence for a Catalytic Mechanism Distinct from Other Gluzincin Metalloproteinases," <i>J. Biol. Chem.</i> 276:4998-5004 (2001).						
Ne	Fülöp et al., "Prolyl Oligopeptidase: an Unusual β-Propeller Domain Regulates Proteolysis," Cell 94:161-170 (1998).						
pl	Gerstein et al., "Structural Mechanisms for Domain Movements in Proteins," <i>Biochemistry</i> 33:6739-6749 (1994).						
Ne	Gerstein and Krebs, "A Database of Macromolecular Motions," <i>Nucleic Acids Res.</i> 26:4280-4290 (1998).						
be	Grams et al., "Structure of Astacin With a Transition-State Analogue Inhibitor," Nature Struct. Biol. 3:671-675 (1996).						
we	Groll et al., "Structure of 20S Proteasome from Yeast at 2.4 Å Resolution," Nature 386:463-464 (1997).						
Ne	Holden et al., "Slow- and Fast-Binding Inhibitors of Thermolysin Display Different Modes of Binding: Crystallographic Analysis of Extended Phosphonamidate Transition-State Analogues," <i>Biochemistry</i> 26:8542-8553 (1987).						
Ne	Holland et al., "Structural Comparison Suggests That Thermolysin and Related Neutral Proteases Undergo Hinge-Bending Motion During Catalysis," <i>Biochemistry</i> 31:11310-11316 (1992).						

EXAMINER

Theil

DATE CONSIDERED

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

ATTY. DOCKET NO. MNM/002	APPLN. NO. 10/659,000
APPLICANTS Michael W. Pantoliano et al.	CONFIRMATION NO. 4943
FILING DATE September 9, 2003	GROUP 1645

	U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
M	Inagami, "The Renin-Angiotensin System," Essays Biochem. 28:147-164 (1994).						
Ne	Kim et al., "Crystal Lisinopril," FEBS_L		Prosophila Angiotensin I 70 (2003).	-Converting	Enzyme Bound	to Captopril and	
Ne			of the Structures of Th y Crystallography," <i>Bio</i> c				
We	Knowles, "To Build	an Enzyme	," Philos. Trans. R. Soc	. London B3	32:115-121 (199	91).	
Ne	Kraut, "How Do En	Kraut, "How Do Enzymes Work?" Science 242:533-540 (1988).					
Ne	Krege et al., "Male-Female Differences in Fertility and Blood Pressure in ACE-Deficient Mice," Nature 375:146-148 (1995).						
Ne	Liu et al., "Arg ¹⁰⁹⁸ is Critical for the Chloride Dependence of Human Angiotensin I-Converting Enzyme C-domain Catalytic Activity," <i>J. Biol. Chem.</i> 276:33518-33525 (2001).						
We	Matthews, "Structural Basis of the Action of Thermolysin and Related Zinc Peptidases," Acc. Chem. Res. 21:333-340 (1988).						
pe	Meng et al., "Automated Docking with Grid-Based Energy Evaluation," J. Comp. Chem. 13:505-524 (1992).						
Ne	Natesh et al., "Crystal Structure of the Human Angiotensin-Converting Enzyme-Lisinopril Complex," Nature 421:551-554 (2003).						
pl	Navia and Murcko, "Use of Structural Information in Drug Design," Current Opinions in Structural Biology 2:202-210 (1992).						
pl	Oefner et al., "Structure of Human Neutral Endopeptidase (Neprilysin) Complexed with Phosphoramidon," J. Mol. Biol. 296:341-349 (2000).						
NC	Oudit et al., "The Role of ACE2 in Cardiovascular Physiology," <i>Trends Cardiovasc. Med.</i> 13:93-101 (2003).						
		111	0/05				

EXAMINER

A11005

DATE CONSIDERED

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

ATTY. DOCKET NO.	APPLN. NO.
MNM/002	10/659,000
APPLICANTS Michael W. Pantoliano et al.	CONFIRMATION NO. 4943
FILING DATE	GROUP
September 9, 2003	1645

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
NC	Pantoliano et al., "Affinity Chromatographic Purification of Angiotensin Converting Enzyme," Biochemistry 23:1037-1042 (1984).						
Ne	Patchett et al., "A N (1980).	lew Class of	Angiotensin-Converting	Enzyme Inh	ibitors," Nature 2	288:280-283	
Ne	Pepine, "Potential F Current Clinical Tria	Role of Angiotals," <i>Clin. Car</i>	tensin-Converting Enzyloid. 20 (Suppl. II):II-58	me Inhibition – II-64 (199)	in Myocardial Is 7).	schemia and	
Me	Rawlings and Barrett, "Evolutionary Families of Metallopeptidases," <i>Methods Enzymol.</i> 248:183-228 (1995).						
Ne	Rockel et al., "A Giant Protease with a Twist: The TPP II Complex from <i>Drosophila</i> Studied by Electron Microscopy," <i>EMBO J.</i> 21:5979-5984 (2002).						
pe	Scapin, "Structural Biology in Drug Design: Selective Protein Kinase Inhibitors," DDT 7:601-611 (2002).						
Ne	Schechter and Berger, "On the Size of the Active Site in Proteases. I. Papain," Biochem. Biophys. Res. Commun. 27:157-162 (1967).						
Ne	Shapiro and Riordan, "Inhibition of Angiotensin Converting Enzyme: Dependence on Chloride," Biochemistry 23:5234-5240 (1984).						
Ne	Skeggs et al., "The Preparation and Function of the Hypertensin-Converting Enzyme," <i>J. Exp. Med.</i> 103:295-299 (1956).						
pe	Soubrier et al., "Two Putative Active Centers in Human Angiotensin I-Converting Enzyme Revealed by Molecular Cloning," <i>Proc. Natl. Acad. Sci. USA</i> 85:9386-9390 (1988).						
Ne	Teague, "Implications of Protein Flexibility for Drug Discovery," Nature Rev. Drug Discovery 2:527-541 –(2003).						
he			g of Angiotensin-Conver sitive Carboxypeptidase				

EXAMINER

HIOLOGE

DATE CONSIDERED

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

ATTY. DOCKET NO.	APPLN. NO.
MNM/002	10/659,000
APPLICANTS Michael W. Pantoliano et al.	CONFIRMATION NO. 4943
FILING DATE	GROUP
September 9, 2003	1645

	U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
pe			ensin-Converting Enzyn nacological Sci. 23:177-		mily: Genomics a	and		
pe	Unno et al., "The S 618 (2002).	tructure of the	Mammalian 20S Prote	asome at 2.	75 Å Resolution,	" Structure 10:609-		
we			ogical Peptides by Hum n. 277:14838-14843 (20		sin-Converting E	Enzyme-Related		
we	Williams et al., "Identification of Two Active Site Residues in Human Angiotensin I-Converting Enzyme,"							
Ne	Zhang et al., "Colle of ACE2 and Is Dev (2001).	ctrin, a Collectelopmentally	ting Duct-Specific Trans Regulated in Embryoni	smembrane ic Kidneys,"	Glycoprotein, Is J. Biol. Chem. 2	a Novel Homolog 76:17132-17139		
					··			
								
					-			
				· · · · · · · · · · · · · · · · · · ·				

EXAMINER

Wated

4/10/06

DATE CONSIDERED